COLLABORATIONS

At the Rheumatology Research Group (GIR), we firmly believe in the power of scientific collaboration to drive progress in knowledge and medical innovation. Over the years, we have worked alongside leading national and international institutions, jointly contributing to the development of projects in key areas such as proteomics, regenerative medicine, cartilage biology, and epigenetics. These collaborations, organized by research line, reflect our commitment to excellence and collaborative work.

  • Joshua Labaer (Biodesign Institute, Arizona State University, USA).
  • Ricardo Rojo (Servicio Inmunología del CHUAC).
  • Peter Nilsson y Jochen Schwenk. Biobank profiling-Affinity Proteomics. KTH Stockholm/SciLife Lab.
  • Ron Heeren. Maastricht MultiModal Molecular Imaging Institute (M4I), The Netherlands.
  • Costantino Pitzalis. William Harvey Research Institute, QMUL, London UK.
  • UDC: Alejandro Pazos, Esperanza Cerdán, Mª Ángeles Bernal Pita da Veiga, Ángeles Cid.
  • IDIS-Hospital de Santiago de Compostela: Antonio González, Miguel Abal.
  • Fernando Corrales, CIMA (Pamplona): Manuel Fuentes, Concha Gil, Anabel Marina, Montserrat Carrascal.
  • RIER-ISCIII: Jose Luis Pablos (Hospital 12 de Octubre), Benjamín Fernández (Hospital Clínico San Carlos), Juan Cañete. Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS, Barcelona).
  • CIBER-BBN: Pilar Marco, Grupo Nanobiotecnología para el Diagnóstico (CSIC, Barcelona), Miriam Royo, Grupo de Nanopartículas y Química de Péptidos (IRB, Barcelona).
  • INIBIC-CHUAC: Jorge Suanzes Hernández (Epidemiología Clínica), Germán Bou (Microbiología), Nieves Domenech (Biobanco), Angélica Figueroa (Oncología).

Gennomic collaboration

  • EpiReumaPt – The First Portuguese Epidemiologic Study of Rheumatic Diseases.
  • National Institute of Health (NIH) – Osteoarthritis Initiative (OAI).
  • Cohorte CHECK – The Netherlands.
  • Johanne Martel Pelletier, Pharmacology Department – University of Montreal, Canada.
  • Frank Roemer, Boston University, USA.
  • Ana M. Valdes, Academic Rheumatology – University of Nottingham, UK.
  • Daniel Arellano, Facultad de Medicina, México.
  • IDIS-Hospital de Santiago de Compostela: Antonio González Martínez-Pedrayo.
  • CNIC: José Antonio Enríquez Dominguez.
  • INIBIC-CHUAC: Guillermo Vázquez González (Grupo de Tecnologías de la Salud), Salvador Pita Fernández (Grupo Epidemiología Clínica y Estadística), Nieves Doménech García (Grupo Biomarcadores Cardíacos), Victor Bautista Hernández (Grupo de Cirugía Cardíaca), Eva Poveda López (Grupo de Virología Clínica), José Luis Fernández García (Grupo de Toxicogenética).
  • Karen Bieback. Institute of Transfusion Medicine and Immunology, Faculty of Medicine Mannheim. University of Heidelberg, Germany.
  • Dina Simes, CIMAR, Universidade do Algarve, Portugal.
  • Antonella Fioravanti, Rheumatology Unit, Department of Medicine Surgery and Neuroscience. University of Siena, Italy.
  • Genogla, Portugal (Dina Simes, Carla Viegas).
  • Vetter (Angela Vela).
  • IBEROS: Pío González, Julia Serra, Grupo Novos Materiais, Universidad de Vigo.
  • CIBER-BBN: Luis Rojo, Julio San Roman, Luis Rodríguez-Lorenzo (GBP-CSIC); José Luis Goméz Ribelles, Gloria Gallego (CBM-UPV), Josep Samitier, Anna Lagunas (IBEC), José A Andrades (LABRET-UMA); María Vallet-Regí, Daniel Arcos (GIBI-UCM).
  • CICA-INIBIC: Jaime Rodriguez, Carlos Jimenez (Grupo QUIMOLMAT).
  • INIBIC-CHUAC: Rosa Meijide, Carlos Vaamonde, Silvia Diaz Prado (Grupo de Investigación en Terapia Celular y Medicina Regenerativa).
  • Martin K. Lotz. The Scripps Research Institute. Department of Molecular and Experimental Medicine. La Jolla, CA (USA).
  • Dr. Paul Robbins, The Scripps Research Institute, Jupiter, Florida, USA.
  • Mohit Kapoor. Division of Genetics and Development, Toronto Western Research Institute, Toronto, Canada.
  • Dr. Jerome Guicheaux y Claire Vinatier, INSERM, Nantes, Francia.
  • Dra. Tonia Vincent, “The Kennedy Institute of Rheumatology”, University of Oxford.
  • Dr. Ivan Shirinsky. Scientific Research Institute of Clinical immunology, Novosibirsk, Russia.
  • Ron Heeren. FOM Institute AMOLF. Science Park 104, 1098 XG Amsterdam, The Netherlands.
  • Alexandrina Ferreiro Mendes. CNC – Centro de Neurociências e Biologia Celular. Universidade de Coimbra, Portugal.
  • Carlos López Otín. Departamento de Bioquímica y Biología Molecular. Universidad de Oviedo.
  • María Isabel Loza. BioFarma Group. Center for Research on Molecular Medicine and Chronic Diseases (CIMUS). Universidad de Santiago de Compostela.
  • Dra. Patricia Díaz Rodríguez, Department of Chemical Engineering and Pharmaceutical Technology, Section Pharmacy and Pharmaceutical Technology. Facultad de Farmacia, La Laguna, Tenerife.
  • Dr. Oscar Yanes Torrado. Universitat Rovira i Virgili, Tarragona; CIBER de Diabetes y Enfermedades Metabólocas asociadas (Ciberdem) del ISCIII.
  • University of Southampton, Faculty of Medicine, UK: Richard Oreffo, Bone & Joint Research Group and Philip Calder, Nutrition Group.
  • University of Seville, Faculty of Pharmacy, Spain: Catalina Alarcón de la Lastra and Marina Sánchez Hidalgo.
  • Hospital for Special Surgery, NYC: Miguel Otero and Mary Goldring.
Scroll al inicio